Brazil Sets Sights On Biogen’s Spinraza For First Risk Sharing Deal
Executive Summary
As Brazil turns to risk sharing agreements to improve access to expensive treatments, the health ministry has its eye on Biogen’s rare disease treatment Spinraza (nusinersen).
You may also be interested in...
Brazil Introduces New Measures To Tackle ‘Judicialization’ Of Access To Medicines
Brazil has announced new measures to try to deal with the costly problem of patients pursuing access to medicines through the courts.
Brazil’s Spiraling Access Suits And The Potential Impact On Companies
Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.